Neurocrine Biosciences (NASDAQ:NBIX) Given New $220.00 Price Target at Canaccord Genuity Group

Posted by Brian Himes on Nov 3rd, 2026

Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) had its price objective lifted by Canaccord Genuity Group from $210.00 to $220.00 in a report released on Tuesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Canaccord Genuity Group‘s price objective points to a potential upside of 51.36% from the company’s current price.

A number of other research analysts have also recently commented on NBIX. Wedbush upped their price target on Neurocrine Biosciences from $185.00 to $194.00 and gave the stock an “outperform” rating in a research note on Monday, August 3rd. Stifel Nicolaus lifted their price objective on Neurocrine Biosciences from $188.00 to $215.00 and gave the company a “buy” rating in a research note on Friday, July 31st. Cantor Fitzgerald boosted their price objective on Neurocrine Biosciences from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Friday, July 31st. Wells Fargo & Company increased their target price on Neurocrine Biosciences from $175.00 to $200.00 and gave the stock an “overweight” rating in a research note on Friday, July 17th. Finally, Truist Financial raised their target price on Neurocrine Biosciences from $200.00 to $213.00 and gave the company a “buy” rating in a report on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $201.82.

Get Our Latest Report on Neurocrine Biosciences

Neurocrine Biosciences Stock Performance

Neurocrine Biosciences stock opened at $145.35 on Tuesday. The company’s 50 day simple moving average is $146.49 and its 200-day simple moving average is $147.45. The company has a market capitalization of $14.77 billion, a price-to-earnings ratio of 21.31, a price-to-earnings-growth ratio of 0.64 and a beta of 0.36. Neurocrine Biosciences has a 1 year low of $122.14 and a 1 year high of $186.12.

Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) last posted its quarterly earnings data on Monday, November 2nd. The company reported $3.29 earnings per share for the quarter, topping analysts’ consensus estimates of $1.91 by $1.38. Neurocrine Biosciences had a net margin of 20.91% and a return on equity of 22.43%. The firm had revenue of $1.12 billion during the quarter, compared to analysts’ expectations of $1.04 billion. During the same quarter last year, the company posted $2.04 EPS. The firm’s quarterly revenue was up 41.3% on a year-over-year basis. Equities analysts expect that Neurocrine Biosciences will post 7.72 earnings per share for the current year.

Insider Activity

In other Neurocrine Biosciences news, insider David Boyer sold 826 shares of the company’s stock in a transaction dated Monday, September 14th. The stock was sold at an average price of $157.45, for a total transaction of $130,053.70. Following the sale, the insider owned 8,722 shares in the company, valued at $1,373,278.90. This represents a 8.65% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Matt Abernethy sold 2,311 shares of the stock in a transaction dated Monday, September 14th. The shares were sold at an average price of $157.20, for a total value of $363,289.20. Following the completion of the sale, the chief financial officer directly owned 42,808 shares in the company, valued at $6,729,417.60. This represents a 5.12% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 4.60% of the stock is owned by corporate insiders.

Institutional Trading of Neurocrine Biosciences

Several hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new position in Neurocrine Biosciences during the 2nd quarter worth approximately $2,310,886,000. Renaissance Technologies LLC raised its holdings in shares of Neurocrine Biosciences by 8.0% in the 1st quarter. Renaissance Technologies LLC now owns 2,418,897 shares of the company’s stock valued at $318,665,000 after purchasing an additional 180,100 shares in the last quarter. First Trust Advisors LP raised its holdings in shares of Neurocrine Biosciences by 97.0% in the 1st quarter. First Trust Advisors LP now owns 959,217 shares of the company’s stock valued at $126,367,000 after purchasing an additional 472,408 shares in the last quarter. Bank of New York Mellon Corp purchased a new stake in shares of Neurocrine Biosciences during the 2nd quarter worth $117,827,000. Finally, Ieq Capital LLC purchased a new stake in shares of Neurocrine Biosciences during the 2nd quarter worth $107,914,000. Institutional investors and hedge funds own 92.59% of the company’s stock.

Neurocrine Biosciences News Summary

Here are the key news stories impacting Neurocrine Biosciences this week:

Positive Sentiment: Strong third-quarter results: Neurocrine reported adjusted earnings of $3.29 per share, up from $2.04 a year earlier and above consensus estimates ranging from $1.91 to $2.67. Revenue increased 41.3% year over year to approximately $1.12 billion, exceeding the roughly $1.04 billion estimate. Neurocrine Biosciences Reports Third-Quarter 2026 Financial Results
Positive Sentiment: Product sales exceeded $1 billion for the first time: Management attributed the milestone to strong demand across its portfolio of medicines, indicating continued commercial momentum and a broader revenue base. Neurocrine Biosciences Crosses $1 Billion in Quarterly Product Sales
Positive Sentiment: INGREZZA guidance raised: Neurocrine increased its 2026 net sales guidance for INGREZZA (valbenazine) to $2.9 billion-$2.925 billion. The upgraded outlook reinforces expectations for sustained demand for the company’s leading commercial product. Neurocrine Biosciences Reports Third-Quarter 2026 Financial Results
Neutral Sentiment: Management’s earnings-call presentations and transcripts provide additional detail on quarterly performance, product demand, and the company’s outlook. Investors will likely focus on whether the strong growth and raised guidance can continue into 2027. Neurocrine Q3 2026 Earnings Call Transcript

About Neurocrine Biosciences

(Get Free Report)

Neurocrine Biosciences, Inc is a San Diego-based biopharmaceutical company focused on discovering, developing and commercializing medicines for neurological, neuroendocrine and psychiatric disorders. The company’s research programs target conditions in which treatments may address significant unmet medical needs.

Neurocrine’s leading product is INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor approved in the United States for the treatment of tardive dyskinesia and chorea associated with Huntington’s disease.